Chicago, USA: June 3, 2025 -- Altis Labs, Inc. (“Altis”) is announcing results presented at The American Society of Clinical Oncology Annual Meeting 2025: in Bayer’s randomized controlled Phase 3 NExUS trial in advanced non-small cell lung cancer, IPRO-Δ predicts OS more accurately than RECIST SLD at Week 13. 

The analysis used baseline and week-13 CT scans from 165 lung cancer patients enrolled in the NExUS trial to compare IPRO-Δ, Altis’ AI-derived survival score, with traditional RECIST assessment including percent change in the sum of longest diameters (ΔSLD).

Key findings include:

-IPRO-Δ had a greater association with OS (HR=1.72, 95% CI: 1.38-2.15) than ΔSLD (HR=1.14, 95% CI: 0.94-1.38)

-IPRO-Δ groups yielded larger OS differences than RECIST-based response categories (PR, SD, PD).

Altis trained IPRO-Δ to predict survival from radiology scans using its proprietary, multimodal database spanning 200,000+ cancer patients with longitudinally linked imaging, clinical, molecular, treatment, and 500,000+ patient years of outcomes data. When applied to clinical trial data, IPRO-Δ offers drug developers a novel measure to improve patient stratification and enhance estimation of treatment effect.

Access the abstract here.

About Altis Labs

Altis Labs is the computational imaging company accelerating clinical trials with AI. Altis has trained proprietary AI models on the industry's largest multimodal training database spanning over 200 million longitudinal images linked to clinical, molecular, treatment, and outcomes data. Top 20 biopharmas use Altis’ AI models to more confidently analyze data from phase 1-4 clinical trials and bring the most effective novel treatments to patients sooner. 

For more information, visit www.altislabs.com, follow @AltisLabs on social media, or email info@altislabs.com.